Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart

Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease
Kroekkiat ChindaNipon Chattipakorn

Abstract

We hypothesized that dipeptidyl peptidase (DPP)-4 inhibitor (vildagliptin) reduces fatal arrhythmias, cardiac dysfunction and infarct size caused by ischaemia-reperfusion (I/R) injury via its attenuation of cardiac mitochondrial dysfunction. In total, 26 rats were randomized to receive either 1 mL normal saline solution or 2.0 mg/kg vildagliptin intravenously (n = 13/group) 30 min prior to a 30-min left anterior descending coronary artery occlusion, followed by a 120-min reperfusion. Arrhythmia scores, cardiac functions, infarct size and mitochondrial function were evaluated. Vildagliptin reduced the infarct size by 44% and mitigated cardiac dysfunction by preserving cardiac function without altering the incidence of cardiac arrhythmias. Vildagliptin increased expression of Bcl-2 and pro-caspase3 in the ischaemic area, whereas Bax and phosphorylated-connexin43/total-connexin43 were not altered. Vildagliptin attenuated cardiac mitochondrial dysfunction by reducing the reactive oxygen species level and mitochondrial swelling. DPP-4 inhibitor provides cardioprotection by reducing the infarct size and ameliorating cardiac dysfunction in I/R hearts by attenuating cardiac mitochondrial dysfunction and cardiomyocyte apoptosis.

References

May 18, 2000·Biochemical Society Transactions·A P HalestrapA O'Toole
Feb 14, 2004·Cardiovascular Research·David García-DoradoMarisol Ruiz-Meana
Jun 3, 2004·European Heart Journal·Jorik R TimmerUNKNOWN Zwolle Myocardial Infarction Study Group
Oct 23, 2004·Circulation Research·Stephan B DanikDavid E Gutstein
Sep 22, 2005·Physiology·Brian O'RourkeMiguel A Aon
Sep 24, 2005·Current Drug Targets. Immune, Endocrine and Metabolic Disorders·S Faubel, C L Edelstein
Nov 10, 2005·Biochimica Et Biophysica Acta·Andrew J TompkinsPaul S Brookes
Jul 11, 2006·Biochimica Et Biophysica Acta·Dmitry B ZorovSteven J Sollott
Nov 1, 2006·International Journal of Clinical Practice·A Barnett
Sep 15, 2007·The New England Journal of Medicine·Derek M Yellon, Derek J Hausenloy
Jun 4, 2008·Cardiovascular Research·Nicholas J SeversStephen Rothery
Feb 7, 2009·Journal of the American College of Cardiology·Leo TimmersImo E Hoefer
Aug 26, 2009·The International Journal of Biochemistry & Cell Biology·M A AonB O'Rourke
Mar 9, 2010·American Journal of Physiology. Heart and Circulatory Physiology·Yumei YeYochai Birnbaum
Nov 20, 2010·Cardiovascular Drugs and Therapy·Barbara HuisamenAmanda Lochner
Nov 26, 2010·International Journal of Cardiology·Borja IbanezJuan J Badimon
Dec 28, 2010·Biochimica Et Biophysica Acta·Gabriel LoorPaul T Schumacker
Apr 26, 2011·Pharmacology & Therapeutics·Fadi G Akar, Brian O'Rourke
Jul 13, 2011·Naunyn-Schmiedeberg's Archives of Pharmacology·Hui-Chun KuMing-Jai Su
Sep 17, 2011·European Heart Journal·Jacob LønborgThomas Engstrøm
Jan 31, 2012·International Journal of Cardiology·Kroekkiat ChindaNipon Chattipakorn
Feb 11, 2012·Endocrine Reviews·John R Ussher, Daniel J Drucker
Apr 13, 2012·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Kroekkiat ChindaNipon Chattipakorn
Oct 11, 2012·PLoS Biology·Gorka BasañezJ Marie Hardwick
Oct 31, 2012·Journal of Cardiovascular Pharmacology·Sirirat SurinkaewNipon Chattipakorn
Jan 4, 2013·Circulation·Alan S GoUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee

❮ Previous
Next ❯

Citations

Dec 4, 2015·Canadian Journal of Physiology and Pharmacology·Nagla A El-Sherbeeny, Manar A Nader
Aug 25, 2015·International Journal of Cardiology·Chao-Jun YangZhi-Xing Fan
Nov 7, 2015·European Heart Journal·Fabrizio MontecuccoThomas H Schindler
Mar 24, 2016·The Journal of Endocrinology·Wanpitak PongkanNipon Chattipakorn
Apr 6, 2016·The Journal of Endocrinology·Nattayaporn ApaijaiNipon Chattipakorn
Aug 21, 2016·The Journal of Endocrinology·Wanpitak PongkanNipon Chattipakorn
Nov 23, 2016·The Journal of Endocrinology·Pongpan TanajakNipon Chattipakorn
Apr 17, 2018·Medicinal Research Reviews·María José Ojeda-MontesSantiago Garcia-Vallvé
Feb 10, 2018·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Pongpan TanajakNipon Chattipakorn
Nov 17, 2017·The Journal of Endocrinology·Pongpan TanajakNipon Chattipakorn
Nov 30, 2018·Expert Review of Clinical Pharmacology·Syed Raza ShahSteven Roark
Jun 2, 2017·American Journal of Physiology. Renal Physiology·George J Dugbartey, Andrew N Redington
Mar 29, 2020·International Journal of Molecular Sciences·Michał WicińskiBartosz Malinowski
Sep 13, 2017·BioMed Research International·Dirk von LewinskiHarald Sourij
May 29, 2018·Medicinal Research Reviews·Katarina TomovicAndrija Smelcerovic
Jul 20, 2018·Naunyn-Schmiedeberg's Archives of Pharmacology·Salma A El-MarasyReham M Abd-Elsalam
Mar 20, 2016·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Melissa LeungVincent W Wong
Oct 21, 2018·International Journal of Molecular Sciences·Amin Al-AwarKrisztina Kupai
Feb 15, 2018·Frontiers in Pharmacology·Defang LiQiusheng Zheng
Jul 21, 2020·Canadian Journal of Physiology and Pharmacology·Hao-Xi ZhaoYongsheng Yu
Aug 20, 2020·Experimental Gerontology·Yunhua YuXianxian Zhao
Apr 23, 2021·Biochemical Pharmacology·Zhigang ZhangYongsheng Yu
Aug 11, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Siripong PaleeNipon Chattipakorn

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis

Software Mentioned

ImageJ
SPSS
LabScribe2

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.